The intermediary Hestbæk Consult handled the pitch, which began in November last year.
DDB Remedy, DDB’s health arm, will create a campaign for the product, dubbed "Project Cool", across Europe, the US and Asia. It is expected to target consumers and healthcare professionals.
The product is thought to relate to Novartis’ US high-strength pain-relief brand Excedrin. The tablet was recalled in the US last year after a series of faulty batches were distributed.
Novartis works with a number of agencies including DraftFCB London, Wunderman Switzerland and Grey Group.
This article was first published on campaignlive.co.uk